Programming gene and engineered-cell therapies with synthetic biologyhttps://t.co/xvKaSGafHV$GILD $CELG $BLUE $BLCM $CLLS pic.twitter.com/gh3bMCz700
— Andy Biotech (@AndyBiotech) February 23, 2018
FDA, EMA and Swissmedic comparison on approval rates: From 2007 to 2016, 134 new drugs were approved by all three agencies. Overall, 66.4% of the drugs were first approved by the FDA, 30.6% by the EMA and 3.0% by Swissmedic https://t.co/lXAo9VQ06N
— Zach Brennan (@ZacharyBrennan) February 23, 2018
New paper from Intellia Therapeutics about in vivo #CRISPR #GeneEditing for liver disease in mice, showing super high levels of editing (over 97% knockdown of transthyretin gene) for potential treatment of #amyloidosis liver disease. https://t.co/QghQc0YdZv
— Ryan Cross the Science Boss (@RLCscienceboss) February 27, 2018
Drug sales and NIH funding activity for the top 20 mechanism-of-action targets https://t.co/G79LaHG2AI pic.twitter.com/OEB1SwsaxD
— Nature Rev Drug Disc (@NatRevDrugDisc) March 2, 2018
Review of 25-years of data by #FDA finds only a small number of oncology products granted accelerated approval fail to verify clinical benefit; while AA brings products to market earlier for patients with life-threatening cancer @JAMAOnc #OCEpub https://t.co/UOnKtzscyt
— Scott Gottlieb, M.D. (@SGottliebFDA) March 2, 2018
Synthetic IL-2 cytokine-receptor pairs could improve T cell cancer therapieshttps://t.co/Ygaj2QCWiS
— Andy Biotech (@AndyBiotech) March 2, 2018
Good ol' IL-2 as the hottest thing in I/O --> $NKTR $ALKShttps://t.co/5E46zCmRwkhttps://t.co/4Un0tXaKVx pic.twitter.com/ERc4CC64aH
Fascinating paper suggesting new classification scheme for adult onset diabetes:
— Ethan Weiss (@ethanjweiss) March 2, 2018
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables https://t.co/gQvUkDOEC2 pic.twitter.com/Tq9Hve8MhZ
Study of NIH peer review of grant proposals suggests a random process -- a lottery -- beats current system. Really? Can't something better be devised? https://t.co/H6W0yInW90 pic.twitter.com/M56rtyzk08
— steve usdin (@steveusdin1) March 5, 2018
Cancer Discovery highlights Umbralisib safety/efficacy profile - $TGTX near 52 wk high ----> PI3Kδ with Less Toxicity Than Previous Inhibitors https://t.co/zl8oEfEqcx
— Paul D. Rennert (@PDRennert) March 7, 2018
Another timely article - review in @NatRevGastroHep on GI toxicities of immune checkpoint inhibitors. Seeing increasing numbers of biopsies for suspected ICI colitis in the past year. https://t.co/MN2VZ3fy7b
— Anirban Maitra (@Aiims1742) March 12, 2018
Nice figure on possible mechanism(s) of gut toxicity.
Ipi > aPD-1 drugs pic.twitter.com/W6bRZaP2Mn
Impressive graphic - the myriad of ways that bacteria resist antibiotics https://t.co/odKEw2YW33 pic.twitter.com/kIcevCBea7
— Jay Hinton (@jay_salsa) March 12, 2018
Very interesting new paper in @NeuroCellPress
— Andy Biotech (@AndyBiotech) March 16, 2018
Cell Therapy Could Improve Brain Function for #Alzheimer’s Diseasehttps://t.co/dzO9YVscAE
Nav1.1-Overexpressing Interneuronhttps://t.co/rCBeUTd2OE pic.twitter.com/CQ9sGmjY5C
RSS Feed
